J. Reome

发表

Ag-Specific Type 1 CD8 Effector Cells Enhance Methotrexate-Mediated Antitumor Responses by Modulating Endogenous CD49b-Expressing CD4 and CD8 T Effector Cell Subpopulations Producing IL-10

K. Rewers-Felkins, M. Dobrzanski, J. Reome, 2008, Immunological investigations.

Effector Cell-Derived Lymphotoxin α and Fas Ligand, but not Perforin, Promote Tc1 and Tc2 Effector Cell-Mediated Tumor Therapy in Established Pulmonary Metastases

R. Dutton, J. Hollenbaugh, Joseph A. Hollenbaugh, 2004, Cancer Research.

Tc1 and Tc2 Effector Cell Therapy Elicit Long-Term Tumor Immunity by Contrasting Mechanisms That Result in Complementary Endogenous Type 1 Antitumor Responses1

R. Dutton, J. Hollenbaugh, Joseph A. Hollenbaugh, 2004, The Journal of Immunology.

Tc 1 and Tc 2 Effector Cell Therapy Elicit Long-Term Tumor Immunity by Contrasting Mechanisms That Result in Complementary Endogenous Type 1 Antitumor Responses 1

R. Dutton, J. Hollenbaugh, Joseph A. Hollenbaugh, 2004 .

Endogenous Type 1 Antitumor Responses Mechanisms That Result in Complementary Long-Term Tumor Immunity by Contrasting Tc1 and Tc2 Effector Cell Therapy Elicit

R. Dutton, J. Hollenbaugh, M. Dobrzanski, 2004 .

CD8-Mediated Type 1 Antitumor Responses Selectively Modulate Endogenous Differentiated and Nondifferentiated T Cell Localization, Activation, and Function in Progressive Breast Cancer1

K. Rewers-Felkins, M. Dobrzanski, J. Reome, 2006, The Journal of Immunology.

Progressive Breast Cancer Localization , Activation , and Function in Differentiated and Nondifferentiated T Cell Selectively Modulate Endogenous CD 8-Mediated Type 1 Antitumor Responses

K. Rewers-Felkins, M. Dobrzanski, J. Reome, 2006 .

Growing Tumor Immunity and Protection to Progressively Subpopulations Promote Long-Term Tumor Effector T Cell + Type 1 and Type 2 CD8

R. Dutton, M. Dobrzanski, J. Reome, 1999 .

Type 1 and Type 2 CD8 Effector T Cell Subpopulations Promote Long-Term Tumor Immunity and Protection to Progressively Growing Tumor

M. Dobrzanski, J. Reome, 1999 .

Adoptive Transfer of Tumor-Specific Tc17 Effector T Cells Controls the Growth of B16 Melanoma in Mice

R. Dutton, Michael Tighe, M. Garcia-Hernandez, 2010, The Journal of Immunology.

CD8 Effector Cell-Mediated Tumor Rejection Perforin in Early and Late Stages of Type 2 Role of Effector Cell-Derived IL-4, IL-5, and

M. Dobrzanski, J. Reome, 2001 .

Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer.

R. Dutton, M. Dobrzanski, J. Reome, 2004, Clinical immunology.

Melanoma in Mice Effector T Cells Controls the Growth of B16 Adoptive Transfer of Tumor-Specific Tc17

R. Dutton, Michael Tighe, H. Hamada, 2010 .

The Effects of Prolonged Administration of 5-Bromodeoxyuridine on Cells of the Immune System1

R. Dutton, B. Helmich, J. Reome, 2000, The Journal of Immunology.

Immunopotentiating role of IFN-gamma in early and late stages of type 1 CD8 effector cell-mediated tumor rejection.

R. Dutton, M. Dobrzanski, J. Reome, 2001, Clinical immunology.

Priming with Cold-Adapted Influenza A Does Not Prevent Infection but Elicits Long-Lived Protection against Supralethal Challenge with Heterosubtypic Virus1

Alan D. Roberts, T. Strutt, S. Swain, 2007, The Journal of Immunology.

Heterosubtypic Virus Protection against Supralethal Challenge Not Prevent Infection but Elicits Long-Lived Priming with Cold-Adapted Influenza A Does

Susan, Alan D. Roberts, T. Strutt, 2006 .

Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating differentiated T cell localization, activation and chemokine production in established breast cancer.

K. Rewers-Felkins, M. Dobrzanski, J. Reome, 2008, Clinical immunology.

Tc17, a Unique Subset of CD8 T Cells That Can Protect against Lethal Influenza Challenge1

T. Strutt, S. Swain, K. McKinstry, 2009, The Journal of Immunology.

Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases.

R. Dutton, M. Dobrzanski, J. Reome, 1999, Journal of immunology.

In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines.

A. Cerwenka, S. Swain, R. Dutton, 1998, Journal of immunology.

Role of Effector Cell-Derived IL-4, IL-5, and Perforin in Early and Late Stages of Type 2 CD8 Effector Cell-Mediated Tumor Rejection1

R. Dutton, M. Dobrzanski, J. Reome, 2001, The Journal of Immunology.

Type 1 and Type 2 CD8+ Effector T Cell Subpopulations Promote Long-Term Tumor Immunity and Protection to Progressively Growing Tumor1

R. Dutton, M. Dobrzanski, J. Reome, 2000, The Journal of Immunology.

Established Pulmonary Metastases T Cell Subpopulations in + 1 and Type 2 CD8 Therapeutic Effects of Tumor-Reactive Type

R. Dutton, M. Dobrzanski, J. Reome, 1999 .

The Rate of the CD8-Dependent Initial Reduction in Tumor Volume Is Not Limited by Contact-Dependent Perforin, Fas Ligand, or TNF-Mediated Cytolysis1

R. Dutton, J. Hollenbaugh, M. Dobrzanski, 2004, The Journal of Immunology.

Tc 17 , a Unique Subset of CD 8 T Cells That Can Protect against Lethal Influenza Challenge 1

Richard, T. Strutt, S. Swain, 2009 .

TNF-Mediated Cytolysis by Contact-Dependent Perforin , Fas Ligand , Reduction in Tumor Volume Is Not Limited The Rate of the CD 8-Dependent Initial

R. Dutton, J. Hollenbaugh, M. Dobrzanski, 2004 .

The Effects of Prolonged Administration of 5-Bromodeoxyuridine on Cells of the Immune System1

R. Dutton, B. Helmich, J. Reome, 2000, The Journal of Immunology.